Laura A Varas

发表

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

Deniz A. Bölükbas, A. Sundstedt, Adnan Deronic, 2022, Journal for immunotherapy of cancer.

Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast.

A. Musacchio, V. Muzio, S. Dueñas‐Carrera, 2006, Biochemical and biophysical research communications.

Multiple gene copy number enhances insulin precursor secretion in the yeast Pichia pastoris

V. Besada, J. Valdés, E. Lamazares, 2005, Biotechnology Letters.

Transcriptional analysis of the dachsous gene uncovers novel isoforms expressed during development in Drosophila

I. Rodriguez, Laura A Varas, Eva Revilla-Yates, 2015, FEBS letters.

Recombinant expression of ShPI-1A, a non-specific BPTI-Kunitz-type inhibitor, and its protection effect on proteolytic degradation of recombinant human miniproinsulin expressed in Pichia pastoris.

R. García-Fernández, Yamile González-González, E. Lamazares, 2011, FEMS yeast research.

Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix.

M. Lindvall, Laura Varas, K. Edvardsen, 2003, Experimental and molecular pathology.

Expression, purification and characterization of porcine pancreatic Carboxypeptidase B from Pichia pastoris for the conversion of recombinant human insulin

F. Avilés, L. Martinez, Manuel Mansur, 2007 .

The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response

M. G. Vallespí, Y. Soria, I. Torréns, 2016 .

Modeling of mini-proinsulin production in Pichia pastoris using the AOX promoter

J. Valdés, Manuel Mansur, Laura Varas, 2003, Biotechnology Letters.

Alpha10 integrin expression is up-regulated on fibroblast growth factor-2-treated mesenchymal stem cells with improved chondrogenic differentiation potential.

J. Richter, B. Johnstone, Laura Varas, 2007, Stem cells and development.

LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

L. Aldana, A. Blanco, I. Torréns, 2017, Clinical & Experimental Metastasis.

Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate.

A. Blanco, D. Urquiza, I. Torréns, 2019, Vaccine.

Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16

I. Torréns, M. Granadillo, A. Batte, 2018, Journal of Cellular Immunotherapy.